Cargando…

Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease

INTRODUCTION: Dopaminergic medications can trigger impulsive-compulsive behaviors (ICBs) in pre-disposed patients with Parkinson's disease (PD), but what this implies on a neurocognitive level is unclear. Previous findings highlighted potentially exacerbated incentive motivation (willingness to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, Andrew, Ortelli, Paola, Carter, Adrian, Ferrazzoli, Davide, Dissanayaka, Nadeeka N., Evans, Andrew, Chye, Yann, Lorenzetti, Valentina, Frazzitta, Giuseppe, Yücel, Murat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889554/
https://www.ncbi.nlm.nih.gov/pubmed/36744102
http://dx.doi.org/10.3389/fnbeh.2022.949406
_version_ 1784880758148562944
author Dawson, Andrew
Ortelli, Paola
Carter, Adrian
Ferrazzoli, Davide
Dissanayaka, Nadeeka N.
Evans, Andrew
Chye, Yann
Lorenzetti, Valentina
Frazzitta, Giuseppe
Yücel, Murat
author_facet Dawson, Andrew
Ortelli, Paola
Carter, Adrian
Ferrazzoli, Davide
Dissanayaka, Nadeeka N.
Evans, Andrew
Chye, Yann
Lorenzetti, Valentina
Frazzitta, Giuseppe
Yücel, Murat
author_sort Dawson, Andrew
collection PubMed
description INTRODUCTION: Dopaminergic medications can trigger impulsive-compulsive behaviors (ICBs) in pre-disposed patients with Parkinson's disease (PD), but what this implies on a neurocognitive level is unclear. Previous findings highlighted potentially exacerbated incentive motivation (willingness to work for rewards) and choice impulsivity (preferring smaller, immediate rewards over larger, delayed rewards) in PD patients with ICBs (PD + ICBs). METHODS: To deeply understand this evidence, we studied 24 PD + ICBs and 28 PD patients without ICBs (PD-ICBs). First of all, patients underwent the assessment of impulsivity traits, mood, anxiety, and addiction condition. We further administered robust objective and subjective measures of specific aspects of motivation. Finally, we explored whether these processes might link to any heightened antisocial behavior (aggression and risky driving) in PD + ICBs. RESULTS: High levels of positive urgency trait characterized PD + ICBs. They choose to exert more effort for rewards under the conditions of low and medium reward probability and as reward magnitude increases. Findings on choice impulsivity show a great tendency to delay discounting in PD + ICBs, other than a high correlation between delay and probability discounting. In addition, we found what appears to be the first evidence of heightened reactive aggression in PD patients with ICBs. Exacerbated incentive motivation and delay discounting trended toward positively predicting reactive aggression in PD + ICBs. DISCUSSION: Our promising results suggest that there might be immense value in future large-scale studies adopting a transdiagnostic neurocognitive endophenotype approach to understanding and predicting the addictive and aggressive behaviors that can arise from dopaminergic medication in PD.
format Online
Article
Text
id pubmed-9889554
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98895542023-02-02 Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease Dawson, Andrew Ortelli, Paola Carter, Adrian Ferrazzoli, Davide Dissanayaka, Nadeeka N. Evans, Andrew Chye, Yann Lorenzetti, Valentina Frazzitta, Giuseppe Yücel, Murat Front Behav Neurosci Behavioral Neuroscience INTRODUCTION: Dopaminergic medications can trigger impulsive-compulsive behaviors (ICBs) in pre-disposed patients with Parkinson's disease (PD), but what this implies on a neurocognitive level is unclear. Previous findings highlighted potentially exacerbated incentive motivation (willingness to work for rewards) and choice impulsivity (preferring smaller, immediate rewards over larger, delayed rewards) in PD patients with ICBs (PD + ICBs). METHODS: To deeply understand this evidence, we studied 24 PD + ICBs and 28 PD patients without ICBs (PD-ICBs). First of all, patients underwent the assessment of impulsivity traits, mood, anxiety, and addiction condition. We further administered robust objective and subjective measures of specific aspects of motivation. Finally, we explored whether these processes might link to any heightened antisocial behavior (aggression and risky driving) in PD + ICBs. RESULTS: High levels of positive urgency trait characterized PD + ICBs. They choose to exert more effort for rewards under the conditions of low and medium reward probability and as reward magnitude increases. Findings on choice impulsivity show a great tendency to delay discounting in PD + ICBs, other than a high correlation between delay and probability discounting. In addition, we found what appears to be the first evidence of heightened reactive aggression in PD patients with ICBs. Exacerbated incentive motivation and delay discounting trended toward positively predicting reactive aggression in PD + ICBs. DISCUSSION: Our promising results suggest that there might be immense value in future large-scale studies adopting a transdiagnostic neurocognitive endophenotype approach to understanding and predicting the addictive and aggressive behaviors that can arise from dopaminergic medication in PD. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9889554/ /pubmed/36744102 http://dx.doi.org/10.3389/fnbeh.2022.949406 Text en Copyright © 2023 Dawson, Ortelli, Carter, Ferrazzoli, Dissanayaka, Evans, Chye, Lorenzetti, Frazzitta and Yücel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Behavioral Neuroscience
Dawson, Andrew
Ortelli, Paola
Carter, Adrian
Ferrazzoli, Davide
Dissanayaka, Nadeeka N.
Evans, Andrew
Chye, Yann
Lorenzetti, Valentina
Frazzitta, Giuseppe
Yücel, Murat
Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
title Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
title_full Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
title_fullStr Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
title_full_unstemmed Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
title_short Motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in Parkinson's disease
title_sort motivational and myopic mechanisms underlying dopamine medication-induced impulsive-compulsive behaviors in parkinson's disease
topic Behavioral Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889554/
https://www.ncbi.nlm.nih.gov/pubmed/36744102
http://dx.doi.org/10.3389/fnbeh.2022.949406
work_keys_str_mv AT dawsonandrew motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT ortellipaola motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT carteradrian motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT ferrazzolidavide motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT dissanayakanadeekan motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT evansandrew motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT chyeyann motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT lorenzettivalentina motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT frazzittagiuseppe motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease
AT yucelmurat motivationalandmyopicmechanismsunderlyingdopaminemedicationinducedimpulsivecompulsivebehaviorsinparkinsonsdisease